Antiallograft antibodies: Relevance, detection, and monitoring

Current Opinion in Organ Transplantation

Volumn 15, Issue 1, 2010, Pages 2-7

  Leffell, Mary S ^a   Zachary, Andrea A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alloantibodies; Antibody mediated rejection; Autoantibodies; Donor specific antibodies; Human leukocyte antigen specific antibodies

Indexed keywords

ALLOANTIBODY; ALLOANTIGEN; AUTOANTIBODY; AUTOANTIGEN; LEUKOCYTE ANTIGEN;

ALLOTRANSPLANTATION; ANTIBODY MEDIATED REJECTION; GRAFT REJECTION; HUMAN; IMMUNOASSAY; IMMUNOLOGICAL MONITORING; REVIEW; RISK ASSESSMENT;

EARLY DIAGNOSIS; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; IMMUNOASSAY; ISOANTIBODIES; ORGAN TRANSPLANTATION; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 75749137002     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283342798     Document Type: Review

References (59)

1. Lefaucher C, Suberbielle-Boissel C, Hill GS, et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008; 8:324-331.
2. Susal C, Döhier B, Sadeghi M, et al. HLA antibodies and the occurrence of early adverse events in the modern era of transplantation: a collaborative transplant study report. Transplantation 2009; 87:1367-1371.
3. Eng HS, Bennet G, Tsiopelas E, et al. Anti-HLA donor-specific antibodies detected in positive B-cell crossmatches by Luminex predict late graft loss. Am J Transplant 2008; 8:2335-2342.
4. Lee PC, Zhu L, Terasaki PI, Everly MJ. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 2009; 88:568-574.
5. Seveso M, Bosio E, Ancona E, Cozzi E. De Novo anti-HLA antibody responses after renal transplantation: detection and clinical impact. Contrib Nephrol 2009; 162:87-98.
6. Cornell LD, Smith RN, Colvin RB. Kidney transplantation: mechanisms of rejection and acceptance. Annu Rev Pathol 2008; 3:189-220.
7. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8:753-760. (Pubitemid 351347767)
8. Ho EK, Vlad G, Colovai AI, et al. Alloantibodies in heart transplantation. Hum Immunol 2009; 70:825-829.
9. Stastny P, Ring S, Lu C, et al. Role of immunoglobulin (Ig)-G and IgM antibodies against donor human leukocyte antigens in organ transplant recipients. Hum Immunol 2009; 70:600-604.
10. Rose ML, Smith JD. Clinical relevance of complement-fixing antibodies in cardiac transplantation. Hum Immunol 2009; 70:605-609.
11. Kraus ES, Parekh RS, Oberai P, et al. Subclinical rejection in stable positive crossmatch kidney transplant patients: incidence and correlations. Am J Transplant 2009; 9:1826-1834.
12. Zachary AA, Leffell MS. Detecting and monitoring human leukocyte antigenspecific antibodies. Hum Immunol 2008; 69:591-604.
13. Fuggle SV, Martin S. Tools for human leukocyte antigen antibody detection and their application to transplanting sensitized patients. Transplantation 2008; 86:384-390.
14. Tait BD, Hudson F, Cantwell L, et al. Luminex technology for HLA antibody detection in organ transplantation. Nephrology 2009; 14:247-254.
15. Breimer ME, Rydberg L, Jackson AM, et al. Multicenter evaluation of a novel endothelial cell crossmatch test in kidney transplantation. Transplantation 2009; 87:549-556.
16. Zachary AA, Montgomery RA, Leffell MS. Defining unacceptable antigens. Curr Opin Organ Transplant 2008; 13:405-410.
17. Reinsmoen NL, Lai C, Vo A, et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 2008; 86:820-825.
18. Zachary AA, Sholander JT, Houp JA, Leffell MS. Using real data for a virtual crossmatch. Hum Immunol 2009; 70:574-579.
19. Claas FH. HLA antibody testing: a tool to facilitate not to prevent organ transplantation. Int J Immunogenet 2008; 35:275-277.
20. Vadiya S. Clinical importance of antihuman leukocyte antigen-specific antibody concentration in performing calculated panel reactive antibody and virtual crossmatches. Transplantation 2008; 85:1046-1050.
21. Kosmoliaptsis V, Bradley JA, Peacock SA, et al. Detection of IgG HLA-specific alloantibodies in renal transplant patients using single-antigen-beads is compromised by the presence of IgM HLA-specific alloantibodies. Transplantation 2009; 87:813-820.
22. Zachary AA, Lucas DP, Detrick B, Leffell MS. Naturally occurring interference in Luminex assays for HLA-specific antibodies: characteristics and resolution. Hum Immunol 2009; 70:496-501.
23. Gebel HM, Moussa O, Eckels DD, Bray RA. Donor-reactive HLA antibodies in renal allograft recipients: considerations, complications and conundrums. Hum Immunol 2009; 70:610-617.
24. Tambur AR, Ramon DS, Kaufman DB, et al. Perception versus reality? Virtual crossmatch: how to overcome some of the technical and logistic limitations. Am J Transplant 2009; 9:1886-1893.
25. Leffell MS, Zachary AA. The role of the histocompatibility laboratory in desensitization for transplantation. Curr Opin Organ Transplant 2009; 14:396-402.
26. Warner P. Nebulous humors: defining alloantibodies in the 21st century. Hum Immunol 2009; 70:623-626.
27. Zachary AA, Houp JA, Vega R, et al. Evaluation of the humoral response in transplantation. In: Detrick B, Hamilton RG, Folds JD, editors. Manual of molecular and clinical laboratory immunology, 7th ed. Washington, District of Columbia, USA: ASM Press; 2006. pp. 1215-1227.
28. Sumitran-Holgersson S. Relevance of MICA and other non-HLA antibodies in clinical transplantation. Curr Opin Immunol 2008; 20:607-613.
29. Dragun D. Humoral responses directed against nonhuman leukocyte antigens in solid-organ transplantation. Transplantation 2008; 86:1019-1025.
30. Zou Y, Stastny P, Süsal C, et al. Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 2007; 357:1293-1300.
31. Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007; 7:408-415.
32. Suarez-Alvarez B, Lopez-Vazquez A, Gonzalez MZ, et al. The relationship of anti-MICA antibodies and MICA expression with heart allograft rejection. Am J Transplant 2007; 7:1842-1846.
33. Kauke T, Kaczmarek I, Dick A, et al. Anti-MICA antibodies are related to adverse outcome in heart transplant recipients. J Heart Lung Transplant 2009; 28:305-311.
34. Smith JD, Brunner VM, Jigjidsuren S, et al. Lack of effect of MICA antibodies on graft survival following heart transplantation. Am J Transplant 2009; 9:1912-1919.
35. Scornik JC, Guerra G, Schold JD, et al. Value of posttransplant antibody tests in the evaluation of patients with renal graft dysfunction. Am J Transplant 2007; 7:1808-1814.
36. Alvarez-Márquez A, Aguilera I, Blanco RM, et al. Positive association of anticytoskeletal endothelial cell antibodies and cardiac allograft rejection. Hum Immunol 2008; 69:143-148.
37. Alvarez-Márquez A, Aguilera I, Gentil MA, et al. Donor-specific antibodies against HLA, MICA, and GSTT1 in patients with allograft rejection and C4d deposition in renal biopsies. Transplantation 2009; 87:94-99.
38. Amico P, Hönger G, Bielmann D, et al. Incidence and prediction of early antibody-mediated rejection due to nonhuman leukocyte antigen-antibodies. Transplantation 2008; 85:1557-1563.
39. Smith JD, Hamour IM, Burke MM, et al. A reevaluation of the role of IgMnon-HLA antibodies in cardiac transplantation. Transplantation 2009; 87:864-871.
40. Fukami N, Ramachandran S, Saini D, et al. Antibodies to MHC class I induce autoimmunity: role in the pathogenesis of chronic rejection. J Immunol 2009; 182:309-318.
41. Issa N, Cosio FG, Gloor JM, et al. Transplant glomerulopathy: risk and prognosis related to antihuman leukocyte antigen class II antibody levels. Transplantation 2008; 86:681-685.
42. Thaunat O, Hanf W, Dubois V, et al. Chronic humoral rejection mediated by anti-HLA-DP alloantibodies: insights into the role of epitope sharing in donorspecific and nondonor specific alloantibodies generation. Transplant Immunol 2009; 20:209-211.
43. Goral S, Prak EL, Kearns J, et al. Preformed donor-directed anti-DP antibodies may be an impediment to successful kidney transplantation. Nephrol Dial Transplant 2008; 23:390-392.
44. Barabanova Y, Ramon DS, Tambur AR. Antibodies against HLA-DQ alphachain and their role in organ transplantation. HumImmunol 2009; 70:410-412.
45. Wahrmann M, Bartel G, Exner M, et al. Clinical relevance of preformed C4dfixing and non-C4d-fixing HLA single antigen reactivity in renal allograft recipients. Transplant Int 2009; 22:982-989.
46. Arnold ML, Dechant M, Doxiadis II, Spriewald BM. Prevalence and specificity of immunoglobulin G and immunoglobulin A noncomplement binding anti-HLA alloantibodies in retransplant candidates. Tissue Antigens 2008; 72:60-66.
47. Phelan D, Mohanakumar T, Ramachandran S, Jendrisak MD. Living donor renal transplantation in the presence of donor-specific human leukocyte antigen antibody detected by solid-phase assay. Hum Immunol 2009; 70:584-588.
48. Taylor CJ, Kosmoliaptsis V, Summers DM, Bradley JA. Back to the future: application of contemporary technology to long-standing questions about the clinical relevance of human leukocyte antigen-specific alloantibodies in renal transplantation. Hum Immunol 2009; 70:563-568.
49. Vlad G, Ho E, Vasilescu ER, et al. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceaseddonor kidney allograft survival. Hum Immunol 2009; 70:589-594.
50. Aubert V, Venetz JP, Pantaleo G, Pascual M. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant. Hum Immunol 2009; 70:580-583.
51. Gupta A, Sinnott P. Clinical relevance of pretransplant human leukocyte antigen donor-specific antibodies in renal patients waiting for a transplant: a risk factor. Hum Immunol 2009; 70:618-622.
52. Bartel G, Regele H, Wahrmann M, et al. Posttransplant HLA alloreactivity in stable kidney transplant recipients: incidences and impact on long-term allograft outcomes. Am J Transplant 2008; 8:2652-2660.
53. Leffell MS, Locke JE, Houp JA, et al. Successful transplantation of patients with low level donor HLA specific antibody without desensitization treatment. Transplantation 2008; 86 (2S):184.
54. Van den Ber-Loonen EM, Billen EVA, Voorter CEM, et al. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation 2008; 85:1086-1090.
55. Opelz G, Claas FHJ. Which human leukocyte antigen antibodies are really clinically relevant? Hum Immunol 2009; 70:561-562.
56. Burns JM, Cornell LD, Perry DK, et al. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant 2008; 8:2684-2694.
57. Zeevi A, Lunz JG III, Shapiro R, et al. Emerging role of donor-specific antihuman leukocyte antigen antibody determination for clinical management after solid organ transplantation. Hum Immunol 2009; 70:L645-650.
58. Eng HS, Bennett G, Bardy P, et al. Clinical significance of anti-HLA antibodies detected by Luminex: enhancing the interpretation of CDC-BXM and important posttransplantation monitoring tools. Hum Immunol 2009; 70:595-599.
59. Locke JE, Zachary AA, Warren DS, et al. Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody. Am J Transplant 2009; 9:2136-2139.